{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:51:24Z","timestamp":1789620684637,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.parkreldis.2005.05.001","type":"journal-article","created":{"date-parts":[[2005,7,13]],"date-time":"2005-07-13T19:42:51Z","timestamp":1121283771000},"page":"469-471","source":"Crossref","is-referenced-by-count":19,"title":["Levetiracetam for the treatment of generalized dystonia"],"prefix":"10.1016","volume":"11","author":[{"given":"Kelly L.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elan D.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Zesiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2005.05.001_bib1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1017\/S0317167100038051","article-title":"Systemic therapy of dystonia","volume":"14","author":"Fahn","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2005.05.001_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(00)00105-9","article-title":"Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic acitivity in a hamster model of paroxysmal dystonia","volume":"391","author":"Loscher","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.parkreldis.2005.05.001_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.parkreldis.2005.05.001_bib4","series-title":"Movement disorders 2","first-page":"332","article-title":"Classification and investigation of dystonia","author":"Fahn","year":"1987"},{"key":"10.1016\/j.parkreldis.2005.05.001_bib5","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology\u2014revised. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218\u201322."},{"key":"10.1016\/j.parkreldis.2005.05.001_bib6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/mds.20233","article-title":"Substantial improvement in a Meige's syndrome patient with Levetiracetam treatment","volume":"19","author":"Zesiewicz","year":"2004","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.parkreldis.2005.05.001_bib7","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1212\/01.WNL.0000127699.78939.73","article-title":"Levetiracetam in the treatment of idiopathic hemifacial spasm","volume":"62","author":"Deleu","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2005.05.001_bib8","unstructured":"Physicians' Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004."},{"key":"10.1016\/j.parkreldis.2005.05.001_bib9","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.parkreldis.2005.05.001_bib10","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","article-title":"Differential expression of synaptic vesicle protein 2 (SV2) isoforms","volume":"14","author":"Bajjalieh","year":"1994","journal-title":"J Neurosci"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802005000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802005000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T09:33:11Z","timestamp":1551864791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802005000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1353802005000921"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2005.05.001","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}